Key result
RAS blockade mitigates brain mitochondrial dysfunction, oxidative stress, and neuroinflammation.
Why the study?
Cardiorenal-metabolic syndrome accelerates age-related changes via the renin-angiotensin system, driving mitochondrial dysfunction, oxidative stress, and neuroinflammation linked to cognitive decline and neurodegenerative diseases.
Does renin-angiotensin system blockade prevent brain mitochondrial dysfunction, oxidative stress, and neuroinflammation in individuals with hypertension, metabolic disorders, and aging?
Does renin-angiotensin system blockade prevent brain mitochondrial dysfunction, oxidative stress, and neuroinflammation in individuals with hypertension, metabolic disorders, and aging?
Angiotensin receptor blockers and ACE2 activators represent promising therapeutic tools for the prevention and treatment of vascular dementia and inflammatory neurodegenerative diseases associated with cardiorenal-metabolic syndrome.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for neuroprotective RAS blockade in cardiometabolic aging; leaves open confirmation in clinical trials.
Although aging is an inherent part of life, it represents a process of progressive dysfunction rather than a fixed biological outcome. Consequently, highly prevalent conditions such as cardiorenal-metabolic syndrome-which encompasses obesity, hypertension (HTN), and metabolic disorders-can accelerate age-related changes. The renin-angiotensin system (RAS) plays a critical role in pathophysiology and affects multiple organs, including the brain. The central nervous system contains both RAS branches: The ACE/Ang II/AT1 and AT2 receptor axis, as well as the ACE2/Ang-(1-7)/Mas receptor axis. Neuroinflammation is a chronic process characterized by glial cell activation triggered by increased production of reactive oxygen and nitrogen species, resulting in oxidative stress. Mitochondria are the primary cellular sites where these processes occur. Under conditions such as metabolic disorders, obesity, HTN, and aging, these reactions are markedly accelerated. Associated mechanisms include insulin resistance, elevated levels of advanced glycation end-products, and disruption of the blood-brain barrier. The consequences of these alterations may include brain dysfunction, cognitive decline, Parkinson's disease, and neurodegenerative conditions such as Alzheimer's disease. This review focuses on the primary effects of therapeutic interventions on mitochondrial function, with particular attention to the modulation of oxidative stress, chronic neuroinflammation, and glial dysregulation. We highlight the strategic use of angiotensin receptor blockers and ACE2 activators as promising tools that may redefine the prevention and treatment of vascular dementia and other neurodegenerative diseases of inflammatory origin.
No takes yet. Share an insight, caveat, or question.
Menéndez et al. (2026) conducted a review in Neuroinflammation, vascular dementia, and cognitive decline associated with hypertension, metabolic disorders, and aging. Renin-angiotensin system blockade was evaluated. Renin-angiotensin system blockade, particularly using angiotensin receptor blockers and ACE2 activators, mitigates brain mitochondrial dysfunction, oxidative stress, and neuroinflammation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: